In endemic areas, both EGFR and HER-2 are co-expressed in approximately 33-87 % of patients with NPC [5, 6], suggesting that EGFRs may be good targets for NPC therapy. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.